A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity - Takeaways - MDSpire

A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

  • By

  • Arianna Sartori

  • Anna Favero

  • Laura Mazzari

  • Giulia Mazzon

  • Alessio Bratina

  • Antonio Bosco

  • Marinella Tomaselli

  • Paolo Manganotti

  • June 16, 2026

  • 0 min

Share

  • 1

    Focal extracorporeal shock wave therapy (fESWT) combined with botulinum toxin injections (BTI) effectively treats spasticity in multiple sclerosis (MS).

  • 2

    In a study of 15 patients with MS, 93.3% reported immediate benefits from the combined treatment, with 53.3% experiencing sustained relief after 28 days.

  • 3

    Significant improvements were observed in spasticity measures, including the Modified Ashworth Scale and Penn Spasm Frequency Scale.

  • 4

    The study highlights fESWT as a non-invasive option that provides immediate relief, while BTI takes longer to achieve its full effect.

  • 5

    Integrating fESWT with BTI may enhance therapeutic outcomes for patients with MS-related spasticity, addressing both immediate and sustained relief.

Original Source(s)

A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

  • by Arianna Sartori, Anna Favero, Laura Mazzari, Giulia Mazzon, Alessio Bratina, Antonio Bosco, Marinella Tomaselli, Paolo Manganotti

  • June 16, 2026

Related Content

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

Associations of Serum Alpha-Linolenic Acid with Disability and Brain Volume in Multiple Sclerosis: A Concise Replication Study